Clinical Trials Logo

Non Clear Cell Renal Carcinoma clinical trials

View clinical trials related to Non Clear Cell Renal Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05220267 Not yet recruiting - Clinical trials for Non Clear Cell Renal Carcinoma

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Start date: February 28, 2022
Phase: Phase 2
Study type: Interventional

The combination of immune checkpoint inhibitors (ICIs) plus angiogenesis inhibitors has demonstrated significant anti-tumor activity in certain cancer. The goal of this study was to evaluate the efficacy and safety of sintilimab (a human programmed death-1 ICI) plus anlotinib (a multi-target tyrosine kinase inhibitor, inhibiting tumor angiogenesis and proliferative signaling) in advanced non clear cell renal cell carcinoma.